Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib + Trametinib in KRAS-mutated NSCLC
NCT02258607Phase 1Terminated
- Sponsor
- GSK
- Start
- Mar 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of momelotinib dihydrochloride in non-small cell lung cancer (NSCLC) (3 arms), sponsored by GSK. Primary endpoints: Dose Limiting Toxicities at 28 days and Disease Control Rate at Week 8. Started Mar 2015; status: terminated.
02
Drugs
momelotinib dihydrochloride
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02258607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02258607.